Table 3.
Median (25% quartile–75% quartile) pharmacokinetic parameters of 7-hydroxymethotrexate in psoriatic patients on low-dose oral methotrexate. The weekly dose was divided into three aliquots of either 2.5 mg (5.5 µmol) or 5 mg (11 µmol) given at 12 h intervals. Samples were taken after the first and third doses at weeks 1 and 13.
| Week 1 | Week 13 | |||
|---|---|---|---|---|
| Dose | 2.5 mg | 5 mg | 2.5 mg | 5 mg |
| AUC(0,12 h) (nmol l−1 h) | 113 (76–127) | 140 (114–198) | 86 (72–152) | 154 (147–239) |
| Cmax1 (nmol l−1) | 14.0 (10.4–14.7) | 16.3 (13.8–25.2) | 10.5 (6.6–13.6) | 20.3 (15.3–27.3) |
| tmax1 (h) | 8 (8–8) | 8 (8–8) | 8 (8–12) | 8 (8–8) |
| AUC(24,36 h) (nmol l−1 h) | 305 (176–334) | 430 (358–563) | 196 (148–304) | 404 (352–639) |
| Cmax3 (nmol l−1) | 29.5 (19.2–31.7) | 39.4 (35.1–55.0) | 19.9 (16.0–28.4) | 36.2 (30.6–55.0) |
| tmax3 (h) | 4 (4–8) | 4 (4–8) | 4 (4–5) | 4 (4–4) |